Scarica l'app Stockscreener
37.08
0.35%
-0.13
Dopo l'orario di chiusura:
36.89
-0.19
-0.51%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$37.21
Aprire:
$37.06
Volume 24 ore:
2.46M
Relative Volume:
0.57
Capitalizzazione di mercato:
$4.19B
Reddito:
-
Utile/perdita netta:
$-99.15M
Rapporto P/E:
-39.87
EPS:
-0.93
Flusso di cassa netto:
$-74.25M
1 W Prestazione:
-3.81%
1M Prestazione:
-9.07%
6M Prestazione:
+29.74%
1 anno Prestazione:
-22.54%
Intervallo 1D:
$36.51
$38.50
Intervallo di 1 settimana:
$36.25
$39.08
Portata 52W:
$18.92
$48.55
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Confronta VKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
37.08 | 4.21B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-29 | Iniziato | Canaccord Genuity | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool
BlackBarn Capital Partners LP Purchases New Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
683 Capital Management LLC Trims Stock Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
Behavioral Patterns of VKTX and Institutional Flows - news.stocktradersdaily.com
Is Early VANQUISH-1 Completion And VK2735 Progress Altering The Investment Case For Viking Therapeutics (VKTX)? - simplywall.st
Frontier Capital Management Co. LLC Increases Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street - Yahoo Finance
3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 - Finviz
Unusual Bullish Options Activity Could Be A Game Changer For Viking Therapeutics (VKTX) - Yahoo Finance
Diadema Partners LP Increases Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Faces Pressure as Rival Obesity Drug Data Emerges - Ad-hoc-news.de
Major Investors Pile Into Viking Therapeutics Stock - Ad-hoc-news.de
Looking At Viking Therapeutics's Recent Unusual Options Activity - Benzinga
460,415 Shares in Viking Therapeutics, Inc. $VKTX Acquired by Jump Financial LLC - MarketBeat
Franklin Resources Inc. Has $703,000 Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics (VKTX): Valuation Check After Faster-Than-Expected Enrollment in Key Obesity Drug Trial - simplywall.st
Norges Bank Takes $46.85 Million Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price? - ts2.tech
Viking Therapeutics: Analysts Project Stock Could More Than Double - AD HOC NEWS
Viking Therapeutics Stock: Prepping For A Critical 2026 (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics (NASDAQ:VKTX) Shares Up 9.4%Here's Why - MarketBeat
Schroder Investment Management Group Buys 150,470 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Will Viking Therapeutics Inc. stock outperform Nasdaq index2025 AllTime Highs & Verified Chart Pattern Trade Signals - Newser
Will Viking Therapeutics Inc. stock outperform international peersEarnings Overview Summary & Low Volatility Stock Suggestions - Newser
What's Up With The Jump In Viking Therapeutics Stock?Viking Therapeutics (NASDAQ:VKTX) - Benzinga
The FDA Is Shaking Things Up; Biotech, Research Stocks Diverge - Investor's Business Daily
How Viking Therapeutics Inc. (1VT) stock expands through international marketsTrade Ideas & Weekly Breakout Opportunity Watchlist - Newser
What consensus target says about Viking Therapeutics Inc. (1VT) stockMarket Performance Summary & Daily Entry Point Alerts - Newser
Will Viking Therapeutics Inc. stock benefit from sector rotationJuly 2025 Big Picture & Low Drawdown Trading Techniques - Newser
How Viking Therapeutics Inc. stock responds to policy changesBuy Signal & Growth Oriented Trade Recommendations - Newser
Viking Therapeutics Stock Gains Momentum on Clinical Progress - AD HOC NEWS
42,134 Shares in Viking Therapeutics, Inc. $VKTX Purchased by Scotia Capital Inc. - MarketBeat
Why Viking Therapeutics Inc. stock appeals to analysts2025 Pullback Review & Stock Portfolio Risk Management - Newser
Will Viking Therapeutics Inc. (1VT) stock deliver compounding returnsJuly 2025 Setups & Expert Curated Trade Setups - Newser
What margin trends mean for Viking Therapeutics Inc. stockEntry Point & Fast Moving Market Watchlists - Newser
Is There a Future for Viking Therapeutics? - AOL.com
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Early Completion and Positive Data in Obesity Trial - simplywall.st
Viking Therapeutics Emerges as a Prime Acquisition Candidate Amid Obesity Drug Advancements - AD HOC NEWS
XTX Topco Ltd Acquires Shares of 36,199 Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. (VKTX) Options Chain - Yahoo! Finance Canada
Why Viking Therapeutics Inc. (1VT) stock attracts HNW investorsQuarterly Trade Report & Proven Capital Preservation Methods - Newser
VKTX Stock Rises 34% in Three Months: Here's What You Should Know - sharewise.com
Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating - MSN
Viking Therapeutics Emerges as a Prime Acquisition Target Following Trial Success - AD HOC NEWS
(VKTX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Viking Therapeutics Stock Gains Momentum on Clinical Trial Milestone - Ad-hoc-news.de
Assessing Viking Therapeutics (VKTX) Valuation After Recent Share Price Recovery - Yahoo Finance
Ensign Peak Advisors Inc Trims Stake in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics (VKTX): Evaluating Valuation After Key Phase 3 Obesity Trial Milestone and New Clinical Data - Sahm
Viking Therapeutics: A Clash of Convictions - Ad-hoc-news.de
SG Americas Securities LLC Makes New $379,000 Investment in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Viking Therapeutics Inc Azioni (VKTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rowland Charles A Jr | Director |
Oct 27 '25 |
Sale |
35.57 |
60,000 |
2,134,278 |
30,000 |
| Lian Brian | President & CEO |
Oct 28 '25 |
Sale |
35.01 |
38,989 |
1,364,923 |
2,419,109 |
| ZANTE GREG | Chief Financial Officer |
Oct 28 '25 |
Sale |
35.00 |
6,185 |
216,481 |
173,592 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):